Results 131 to 140 of about 207,197 (306)

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, EarlyView.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source

Multi-COBRA hemagglutinin formulated with cGAMP microparticles elicits protective immune responses against influenza viruses

mSphere
In humans, seasonal influenza viruses cause epidemics. Avian influenza viruses are of particular concern because they can infect multiple species and lead to unpredictable and severe disease.
Xiaojian Zhang, Hua Shi, Dylan A. Hendy, Eric M. Bachelder, Kristy M. Ainslie, Ted M. Ross   +5 more
doaj   +1 more source

RBD‐SD1 Nanoparticle Vaccines From DPP4‐Using Merbecoviruses Elicit a Cross‐Reactive Antibody Response but Limited Cross‐Protective Immunity

Biotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles displaying RBD‐SD1 from MERS‐CoV, NL140422, and HKU4 elicited robust and cross‐reactive IgG responses in mice. Only MERS‐CoV RBD‐SD1 induced neutralizing antibodies against MERS‐CoV and protected human DPP4 mice from a MERS‐CoV challenge, indicating conserved serologic but limited cross‐neutralizing epitopes.
Peter J. Halfmann, Jeong Soo Lee, Tong Wang, Augustine Duffy, Janie E. Rogers, Natasha Chen, Elizabeth Frimpong, Carmen Rai, Yoshihiro Kawaoka, Ravi S. Kane   +9 more
wiley   +1 more source

A Killer Flu? [PDF]

, 2005
Examines shortfalls in available anti-viral medication and hospital capacity to respond to an epidemic, compares U.S. preparedness to that of the United Kingdom and Canada, and offers recommendations designed to boost America's ...

core  

Counting cases, conserving species: addressing highly pathogenic avian influenza in wildlife

Biological Reviews, EarlyView.
ABSTRACT Highly pathogenic avian influenza (HPAI) has become a critical threat to wildlife, shifting from a seasonal epizootic to a persistent, year‐round panzootic with global consequences. Here, we summarise the origin, evolutionary mechanisms, and expanding host range of the current H5N1 virus (clade 2.3.4.4b) and assess its impact on wildlife. Over
Ulrich Knief, Sandra Bouwhuis, Anja Globig, Anne Günther, Wouter Courtens   +4 more
wiley   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source

Advances in protein subunit vaccines against H1N1/09 influenza

Frontiers in Immunology
The A/H1N1pdm09 influenza virus, which caused the 2009 pandemic, has since become a recurring strain in seasonal influenza outbreaks. Given the ongoing threat of influenza, protein subunit vaccines have garnered significant attention for their safety and
Yu Zhang, Yu Zhang, Jingyao Gao, Wenqi Xu, Xingyu Huo, Jingyan Wang, Yirui Xu, Wenting Ding, Zeliang Guo, Rongzeng Liu   +9 more
doaj   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

The need for novel influenza vaccines in low- and middle-income countries: A narrative review

Brazilian Journal of Infectious Diseases
Influenza viruses cause 3–5 million severe cases and 300,000–600,000 deaths worldwide. Most of the disease burden is in Low- and Middle-Income Countries (LMICs) owing to factors such as high population density, infrastructure challenges, poor quality ...
Julia R. Spinardi, Karan B. Thakkar, Verna L. Welch, Oladayo Jagun, Moe H. Kyaw   +4 more
doaj   +1 more source

Production and Purification of Mesenchymal Stem Cell‐Derived Extracellular Vesicles Using Preferential Exclusion Chromatography

ELECTROPHORESIS, EarlyView.
A scalable purification strategy using hydroxyl (OH) monolithic chromatography enables efficient isolation and direct concentration of MSC‐EVs from adherent and microcarrier‐based upstreams. This approach supports process scale‐up while ensuring high purity suitable for therapeutic EV manufacturing.
Katja Vrabec, Andrej Raspor, Darja Božič, Nastja Bizjak Ternik, Ana Železnik, Valentina Novak, Ivana Petrović Koshmak, Maja Leskovec, Aleš Štrancar   +8 more
wiley   +1 more source